Substrate In Vitro Evidence:
1. Wild-type MXR, two mutant variants found in drug-selected tumor cells (R482 G and R482T), and a catalytic center mutant (K86M) were expressed in Sf9 insect cells. The K86M was not functional. Wild-type and the R482 mutants transported mitoxantrone and Hoechst 33342; only the R482 mutants transported Rho123. MXR-specific transport was inhibited by fumitremorgin C. Ozvegy, C et al. JBC 2002 Dec 13, 277(50):47980-90 PMID 12374800.
2. Wild-type MXR and the R482T mutant were introduced to MCF7 cells. Both transfectants showed strong resistance to indolocarbazoles. The indolocarbazole compound A was transported by membrane vesicles. This transport was inhibited by another indocarbazole compound, but not by mitoxantrone. Nakagawa, R et al. Biochem Biophys Res Comm 2002 Dec 13, 299(4):669-75 PMID 12459192.
3. SN-38-selected PC-6/SN2-5H human lung carcinoma cells overexpress MXR. Membrane vesicles from these cells transported SN-38 and SN-38-glucuronide. Nakatoni, K et al. Biochem Biophys Res Comm 2001 Nov 9, 288(4):827-32 PMID 11688982.
4. When overexpressed in cell lines, MXR confers high levels of resistance to anthracyclines, mitoxantrone, bisantrene, and the camptothecins topotecan and SN-38. Ejendal, KR; Hrycyna, CA. Curr Prot Pept Sci 2002 Oct, 3(5):503-11 PMID 12369998.
Substrate In Vivo Evidence:
1. MXR may play a role in MDR in acute myeloid leukemia. Ejendal, KR; Hrycyna, CA. Curr Prot Pept Sci 2002 Oct, 3(5):503-11 PMID 12369998.
Tissue Distribution Evidence:
1. IHC demonstrated MXR expression at the blood-brain barrier (the luminal surface of microvessel endothelium). Cooray, HC et al. Neuroreport 2002 Nov 15, 13(16):2059-63 PMID 12438926.
2. RT-PCR showed that MXR expression varied widely in breast cancer cell lines and in primary breast carcinomas. There was no indication that elevated MXR expression in breast carcinomas confers resistance to anthracyclines. Faneyte, IF et al. Clin Cancer Res 2002 Apr, 8(4):1068-74 PMI 11948115.
3. MXR is abundantly expressed in placenta, liver, intestine, and stem cells. Ejendal, KR; Hrycyna, CA. Curr Prot Pept Sci 2002 Oct, 3(5):503-11 PMID 12369998.
Transmembrane prediction: Non-synonymous amino acid changes shown in red, indels (insertions and deletions) in blue, and synonymous changes in green. Exon(s) indicated by black outlines.
Copyright 2009, UCSF Pharmacogenetics of Membrane Transporters. All rights reserved.